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Resveratrol and cognitive decline: a clinician perspective
Arrigo F.G. Cicero1, Massimiliano Ruscica2, Maciej Banach3
A b s t r a c t
Resveratrol (3,5,4′-trihydroxystilbene) belongs to a family of polyphenolic com-
pounds known as stilbenes, particularly concentrated in grape and red wine. 
The aim of our review was to critically review the available evidence of resvera-
trol effects on brain function and its potential impact on therapy. In preclinical 
models of cognitive decline, resveratrol displays potent antioxidant activity by 
scavenging free radicals, reducing quinone reductase 2 activity and upregu-
lating endogenous enzymes. Resveratrol also inhibits pro-inflammatory en-
zyme expression, reduces nuclear factor-κB activation and cytokine release. 
Treatment with resveratrol can affect multiple signaling pathway effectors 
involved in cell survival, programmed cell death and synaptic plasticity. Di-
rect and/or indirect activation of the deacetylase sirtuins by resveratrol has 
also been suggested. In humans, clinical evidence derived from randomized 
clinical trials suggests that resveratrol is able to improve cerebral blood flow, 
cerebral vasodilator responsiveness to hypercapnia, some cognitive tests, per-
ceived performances, and the Aβ40 plasma and cerebrospinal fluid level. 
Key words: clinical trials, cognitive function, neuroprotection, preclinical 
models, resveratrol.
Introduction
Resveratrol (3,5,4′-trihydroxystilbene) belongs to a family of polyphe-
nolic compounds known as stilbenes, particularly concentrated in grape 
and red wine [1, 2]. Resveratrol is also one of the phytoalexins, a group 
of low-molecular-mass substances with antimicrobial activity, produced 
by plants as a defense response to some exogenous stimuli, such as UV 
radiation, chemical stressors, and, particularly, microbial infections [3]. 
The compound exists in two isomeric forms. The trans isomer occurs in 
the berry skins of most grape cultivars, and its synthesis is stimulated by 
UV light, injury, and fungal infection. The cis isomer is produced by UV 
irradiation of the trans isomer; it is generally absent or only slightly de-
tectable in grapes but is originated during vinification [4]. Most research 
on resveratrol concerns the trans isomer, owing to its natural presence in 
grapes and its greater stability [5].
A  huge pre-clinical literature and some clinical evidence recently 
demonstrated a potentially relevant impact of resveratrol on central ner-
vous system functionality [6].
The aim of our review was to critically resume the available evidence of 
resveratrol effects on brain function and its potential impact on therapy.
Nutraceuticals
Resveratrol and cognitive decline: a clinician perspective
Arch Med Sci 4, July / 2019 937
Neuroprotection in preclinical models
Postoperative cognitive dysfunction represents 
a  severe neurological complication in approxi-
mately 25% of elderly people. Indeed, in the hip-
pocampus, by inducing over-production of pro-in-
flammatory cytokines (i.e., tumor necrosis factor 
(TNF)-α and interleukin (IL)-1β), isoflurane anes-
thesia impairs synaptic plasticity leading to neu-
rodegeneration with a  consequent deficit in the 
cognitive function [7, 8]. In this context, in aged 
mice, the intraperitoneal injection of 100 mg/kg 
resveratrol for 7 days attenuates the isoflurane 
anesthesia hippocampus-dependent cognitive 
impairment through anti-inflammatory and an-
ti-apoptosis effects [9]. Among the possible mo-
lecular mechanisms beyond these effects, the in-
volvement of sirtuin (SIRT) 1 has raised particular 
interest. It belongs to the sirtuin family of NAD-de-
pendent protein deacetylases and it is a deacety-
lase for several metabolic and signaling proteins 
involved in the stress response, apoptosis, mito-
chondrial function, self-renewal, and neuroprotec-
tion [10]. In particular, in neurons, SIRT1 is able 
to deacetylate p53 at the Lys residues (Lys373 
and/or Lys382) and protect various cells from 
DNA damage-induced apoptosis [11]. As a further 
confirmation, studies in cells, primary neurons, 
and mouse models described SIRT1 to be a neu-
roprotective mediator as well as a central player 
in counteracting neurodegeneration [12]. Resver-
atrol is one of the polyphenols able to modulate 
SIRT1 expression and activity. By inducing SIRT1, 
resveratrol may promote neurite outgrowth and 
enhance neural plasticity in the hippocampal re-
gion [13]. The importance of this pathway has also 
been described in a rat model of induced neuro-
pathological Alzheimer disease (AD)-like pattern; 
the activation of SIRT1 by resveratrol (30 mg/kg/
day per 8 weeks) attenuated the hyperphosphor-
ylation of tau protein induced by the intracerebro-
ventricular injection of streptozotocin, confirming 
the role of resveratrol in protecting hippocampus 
neurons from tau hyperphosphorylation and cog-
nitive impairment [14].
Resveratrol also induces neurogenesis and mi-
tochondrial biogenesis by enhancing AMP-activat-
ed protein kinase (AMPK), which is known to stim-
ulate neuronal differentiation and mitochondrial 
biogenesis in neurons. These effects are indepen-
dent of SIRT1 involvement, evidence supported by 
the use of SIRT1 inhibitors or studies conducted 
in the brain of SIRT1 knock-out mice [15]. It is im-
portant to highlight that a tight interplay between 
SIRT1 and AMPK does exist [16]. In a mouse mod-
el of familial AD, it has been demonstrated that 
an equilibrium among SIRT1 and AMPK signaling, 
mitochondrial status and inflammatory changes 
is mandatory for the effect of resveratrol in the 
protection against Aβ plaque formation and cog-
nitive loss [17]. The evidence of a neuroprotective 
effect of resveratrol has been further corroborated 
in in vitro rat hippocampal H19-7 neuronal cells in 
which a 2-h pretreatment with resveratrol (75 mM) 
attenuated the Aβ-induced oxidative damage and 
the decrement of proteins essential for synaptic 
maturity and plasticity [18]. Another feature im-
paired in AD and that may be rescued by resver-
atrol is neurovascular coupling. In a mouse model 
of aging recapitulating cerebrovascular deficits of 
cortical function, treatment with resveratrol res-
cued cortical neurovascular coupling responses, 
an effect mediated by the down-regulation of 
cortical expression of NADPH and the reduction of 
oxidase-derived ROS production [19]. Considering 
that in the rat aorta SIRT1 inhibits NADPH oxidase 
activation and protects endothelial function, this 
pathway cannot be excluded in understanding the 
link between resveratrol and cerebromicrovascu-
lar endothelial function [20].
Besides the involvement of SIRT1 and AMPK, 
a genome-wide gene expression analysis showed 
how, in streptozotocin-induced diabetic rats, res-
veratrol normalized the hippocampal expression 
of genes implicated in neurogenesis and synaptic 
plasticity (Hdac4, Hat1, Wnt7a, ApoE) and reduced 
that of Jak-Stat pro-inflammatory signaling (IL-15, 
IL-22, Socs2 and Socs5) [21]. In a  rodent model 
of vascular dementia, resveratrol supplementa-
tion induced hippocampal nerve growth factor 
expression, attenuating pyramidal cell death in 
the CA1 hippocampal sub-region and improving 
spatial working memory [22]. Further evidence on 
the neuroprotective effect of resveratrol on vascu-
lar dementia came from a study reporting how in 
a  rat model of permanent bilateral common ca-
rotid artery occlusion, the daily administration of 
resveratrol improved learning and memory ability 
as evaluated by the Morris water maze test; the 
escape latency and escape distances were signifi-
cantly shorter in the animals treated with resver-
atrol. Moreover, upon resveratrol administration, 
levels of malonyldialdehyde, a marker of oxidative 
stress in neurodegenerative disease, were de-
creased in cerebral cortex and hippocampus; con-
versely, resveratrol resulted in increased superox-
ide dismutase activity and glutathione levels [23].
Even if the effect of resveratrol on cognitive 
function is magnified in extreme models, it is 
interesting to highlight that resveratrol appears 
effective also in models of mild stress. In rats ex-
posed to chronic unpredictable mild stress, able 
to induce cognitive deficits, the chronic adminis-
tration of resveratrol (20 mg/kg/day) significantly 
attenuates the deficit in emotional learning and 
spatial memory. Analysis of the hippocampus 
showed that, compared to stressed rats, resver-
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atrol prevented the decrement of brain-derived 
neurotrophic factor [24], a key molecule of hippo-
campal plasticity [25].
In the context of insufficient sleep, a model of 
cognitive decline, the effects of polyphenols (in-
cluding resveratrol) on memory deficits have been 
described. Resveratrol significantly improves sleep 
deprivation-induced contextual memory deficits, 
through the activation of two independent but 
interrelated pathways, namely, cAMP-response el-
ement-binding protein and mammalian target of 
rapamycin (mTOR) signaling pathways [26]. The 
positive impact of resveratrol on cognitive func-
tion in old rats (20 months) could be related to 
direct modulation of neurotransmission. Chronic 
administration of resveratrol (20 mg/kg/day for 
4 weeks) leads to an increase of serotonin levels, 
in the pineal gland, in the hippocampus, and in 
the striatum, and of noradrenaline and dopamine, 
in the hippocampus and in striatum, respective-
ly. These changes are to be ascribed to increased 
activity of tryptophan hydroxylase-1 (463% in the 
pineal gland), tryptophan hydroxylase-2 (70 and 
51% in the hippocampus and striatum, respec-
tively), and tyrosine hydroxylase (150 and 36% in 
the hippocampus and striatum, respectively), all 
enzymes involved in monoamine syntheses [27].
Finally, recent data on rats in late middle-age 
highlighted how the effect of resveratrol in im-
proving memory and mood function is mainly due 
to the modulation of hippocampus plasticity and 
the suppression of chronic low-level inflammation, 
steps improving several age-related changes [28].
These neuroprotective actions of resveratrol 
have been summarized in Figure 1 [29].
Effects on cognitive decline in humans
Cognitive deficits were shown to be associated 
with higher levels of reactive oxygen (ROS) and ni-
trogen species: indeed, oxidative stress seems to 
precede the formation of senile plaques [30]. Res-
veratrol has potent antioxidant activity that could 
have a  role in preventing neurodegeneration in 
Alzheimer’s disease [31]. Particularly, it scavenges 
free radicals, protects neurons and microglia [32, 
33] and attenuates Aβ-induced intracellular ROS 
accumulation [34]. The treatment of a hippocam-
pal cell line with resveratrol attenuated ROS pro-
duction and mitochondrial membrane-potential 
disruption; moreover, it restored the normal levels 
of glutathione (GSH) depleted by Aβ1-42 [35].
Resveratrol may also attenuate Aβ-induced 
intracellular ROS accumulation [36]. It induces 
the up-regulation of cellular antioxidants (i.e., 
glutathione) and the gene expression of phase 
2 enzymes, protects against oxidative and elec-
trophilic injury [37], and potentiates the HO-1 
pathway [38]. Another important pathological 
hallmark of Alzheimer’s disease is represent-
ed by brain inflammation that contributes to 
the neuronal damage and enhanced Aβ for-
mation [39]. As reported above in detail, res-
veratrol interferes with the neuroinflammatory 
process [40], and suppresses the activation of 
astrocytes and microglia [41, 42], and TNF-α 
and NO production by inhibiting NF-κB activa-
tion and p38 mitogen-activated protein kinase 
phosphorylation [43]. It also blocks the expres-
sion of cyclooxygenase (COX)-2 and inducible 
NO synthase (iNOS) [44]. Resveratrol treatment 
was also shown to reverse the Aβ-induced iNOS 
overexpression [45] and exert anti-inflammatory 
effects as it inhibits TNF-α, interleukin (IL)-1β, 
and IL-6 expression [46], and signal transducer 
and activator of transcription 1 (STAT1) and STAT3 
phosphorylation [47].
The neuroprotective effect of resveratrol has 
been tested in some randomized, double-blind, 
placebo-controlled clinical trials [48]. Kennedy 
et al. [49] evaluated the effect of a single oral dose 
of resveratrol on mental function and cerebral blood 
flow (CBF) in the frontal cortex of young healthy hu-
mans. The enrolled subjects received three single 
dose treatments: placebo, 250 mg trans-resveratrol, 
and 500 mg trans-resveratrol. Following adminis-
tration, resveratrol significantly increased CBF in 
a dose-dependent manner, but cognitive function 
did not improve acutely. The effect of resveratrol 
on CBF was improved by the contemporaneous ad-
ministration of piperine 20 mg (probably because 
of a direct effect of piperine on CBF, since resvera-
trol plasma level was just shown not to be affected 
by piperine co-administration) [50].
The same authors carried out a  randomized, 
double-blind, placebo-controlled, parallel-groups 
study, a total of sixty adults aged between 18 and 
30 years receiving either placebo or resveratrol 
for 28 days. The results showed that the cogni-
tive effects of resveratrol on day 1 were restrict-
ed to more accurate but slower serial subtraction 
task performance. The only cognitive finding on 
day 28 was a  beneficial effect of resveratrol on 
the accuracy of the 3-Back task before treatment 
consumption. Subjective ratings of ‘fatigue’ were 
significantly lower across the entire 28 days in the 
resveratrol condition. Resveratrol also resulted in 
modulation of CBF parameters on day 1, as as-
sessed by near-IR spectroscopy [51].
A further crossover clinical trial was designed 
to evaluate the effects of resveratrol on circu-
latory function and cognitive performance in 
obese adults [52]. Participants were randomized 
to consume a capsule containing either 75 mg of 
resveratrol or a color-matched placebo daily for 
6 weeks. Then, participants were crossed over 
to an alternate dose for another 6 weeks. More-
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Figure 1. Summary of the neuroprotective action of resveratrol. Resveratrol displays potent antioxidant activity by 
scavenging free radicals and metals, protecting against NO toxicity, reducing QR2 activity and upregulating endoge-
nous enzymes such as glutathione peroxidase, AMPK and LKB1. Resveratrol also inhibits pro-inflammatory enzyme 
(i.e., COX-1 and -2) expression, reduces NF-κB activation as well as PGE2, NO, and TNF-α production, and cytokine 
release. It may promote Aβ clearance. Treatment with resveratrol can affect multiple signaling pathway effectors 
involved in cell survival (AMPK, PI3-k and AkT), programmed cell death (caspase-3/12, Bax, and cytochrome c)  
and synaptic plasticity (ERK1/2). Direct and/or indirect activation of the deacetylase sirtuins by resveratrol has also 
been suggested.
AMPK – AMP-activated protein kinase, COX – cyclooxygenase, ERK – extracellular signal-regulated kinase-1 and -2 (ERK1/2), 
LKB1 – liver kinase B1, NF-κB – nuclear factor κB, NO – nitric oxide, PGE2 – prostaglandin E2, PI3-k – phosphoinositide 3-kinase, 
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over, following the assessments in weeks 6 and 
12, after an hour participants consumed a single 
additional dose of the supplement. The primary 
outcome was to measure the degree of change 
in vasodilator function assessed by flow-medi-
ated dilatation (FMD) in the brachial artery. Res-
veratrol supplementation was found to be well 
tolerated and induced a  23% increase in FMD 
compared with placebo. Moreover, a single dose 
of resveratrol (75 mg) following chronic resvera-
trol supplementation resulted in an acute FMD 
response 35% greater than placebo. However, 
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attention and concentration were unaffected by 
chronic resveratrol supplementation [53]. Witte 
et al. [54] carried out a study aiming to assess 
the ability of resveratrol, given over 26 weeks, to 
enhance the cognitive performance. Overweight 
older adults were randomly divided into an ac-
tive treated group receiving 200 mg/day of res-
veratrol in a formulation with quercetin 320 mg 
[53], in order to increase its bioavailability, and 
a control group, placebo treated. Volume, micro-
structure, and functional connectivity of the hip-
pocampus were explored by magnetic resonance 
imaging. Resveratrol supplementation induced 
retention of memory and improved the function-
al connectivity between the hippocampus and 
frontal, parietal, and occipital areas, compared 
with placebo [55]. The changes in resting-state 
functional connectivity networks of the hippo-
campus after resveratrol intake were linked with 
behavioral improvements. Also, glucose metab-
olism was improved and this may account for 
some of the beneficial effects of resveratrol on 
neuronal function. These data have been recent-
ly confirmed in another trial by Köbe et al. [55]. 
A  long-term (52-week), larger (n = 119) trial of 
resveratrol in individuals with mild-to-moderate 
AD was also conducted [56]. Participants were 
recruited and randomly divided into a  placebo 
group and a  resveratrol group (500 mg orally 
once daily with dose escalation by 500 mg in-
crements every 13 weeks, ending with 1000 mg 
twice daily). The levels of Aβ
40 in the cerebrospi-
nal fluid and plasma declined more in the place-
bo group than the resveratrol-treated group with 
a  significant difference at week 52 (note that 
Aβ
40 levels decline as dementia advances). The 
trial also confirmed that resveratrol was safe and 
well tolerated. Recently, Wong et al. [57] carried 
out a balanced crossover clinical trial to evalu-
ate the effect of resveratrol supplementation 
on cerebrovascular function, in type 2 diabe-
tes adult patients. Participants were random-
ly allocated to receive placebo or resveratrol 
at doses of 75 mg, 150 mg, or 300 mg, taken 
as a  single dose during four intervention vis-
its that took place at seven-day intervals over 
4 weeks. The main outcome was to determine 
the most effective dose of resveratrol to im-
prove the cerebral vasodilator responsiveness 
to hypercapnia in the middle cerebral artery, 
using transcranial Doppler ultrasound. Resver-
atrol consumption significantly increased ce-
rebral vasodilator responsiveness in the mid-
dle cerebral artery at all tested doses, and the 
maximum improvement was observed with the 
lowest one. In a  more recent 14-week study 
carried out on post-menopausal women, the 
improved cerebral vasodilator responsiveness 
was also associated with improvement in cog-
nitive function scores [58], which further con-
firms the possible usefulness of resveratrol in 
subjects with cognitive decline. 
Discussion
Senile dementia is increasing worldwide sub-
stantially, paralleling the “graying” of the world’s 
population [59]. In particular, recent statistics sug-
gest that mild cognitive impairment affects 5.5 
to 7.7% of subjects aged more than 60 years old 
and 22% of those over 70 years old [60], more fre-
quently in those with neuropsychiatric symptoms 
[61]. Faced with this epidemiology, it is necessary 
to search for any tools able to slow the progress 
of this dementia. Several genetic, nutritional and 
metabolic factors have been suggested to influ-
ence the risk of cognitive impairment and de-
mentia in older adults [62, 63]. Both vascular pa-
thology and inflammation have been proposed to 
explain how these factors can induce brain dam-
age and dementia [64, 65]. Some botanicals seem 
to counteract these pathogenetic mechanisms 
[66]. Based on the above summarized evidence, 
resveratrol seems to be a dietary component with 
a specific neuroprotective action with some pos-
itive effect on human cognitive decline. In fact, 
beyond its positive effects on the central nervous 
system, resveratrol seems also to be able to act 
on multiple cellular targets and therefore have 
a variety of biological effects, potentially useful in 
elderly comorbidities, even if it has to be clearly 
demonstrated in long-term randomized clinical 
trials [67].
In particular, even if resveratrol seems not to 
have a specific positive impact on lipid profile [68], 
it seems to exert an improving effect on a number 
of metabolic syndrome components such as insu-
lin resistance [69] and blood pressure [70].
The main problems related to the therapeutic 
or preventive use of resveratrol are linked to its 
low oral bioavailability and its short half-life in 
serum [71]. However, pharmaceutical technol-
ogies seem to be able to improve the oral bio-
availability of resveratrol [72, 73]. On the other 
hand, the tolerability and safety profile of res-
veratrol is very high and no clinically significant 
pharmacological interaction of this nutraceuti-
cal with conventional drugs is known. This is of 
particular interest since the most effective drugs 
for dementia are usually not well tolerated, thus 
being not indicated for the treatment of the first 
disease stages [74], while the pharmacological 
improvement of cardiovascular risk factors has 
only a limited efficacy [75, 76].
In conclusion, long-term treatment with ade-
quate dosages of resveratrol with improved bio-
availability could exert clinically significant protec-
tive effects against cognitive decline in humans.
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